LA JOLLA, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces that it successfully achieved enrollment of the target number of participants in its COMBAT-ALS Phase 2b/3 clinical trial of MN-166 (ibudilast). MN-166 is currently in development for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Related Questions
How will the successful enrollment milestone affect MNOV's short‑term stock momentum and trading volume?
What are the expected timelines for data readout from the COMBAT‑ALS trial and how might that influence the share price volatility?
How does MNOV's progress with MN‑166 compare to other ALS pipeline candidates in terms of trial design, funding and potential market impact?